Home > What has the HARMONY Alliance achieved so far?

What has the HARMONY Alliance achieved so far?


The large number of stakeholders across different European countries makes a fragmented playing field, from basic hematology research all the way to approval processes for new medicines. The HARMONY Alliance was created to fill a specific need in blood cancer treatments. HARMONY functions as the interface between all stakeholders. Never has a European public-private initiative had such ambitious goals for international collaboration in big data and HMs. 

What has HARMONY achieved so far?

Several key milestones have been reached since the HARMONY Alliance was established:

With these achievements, researchers are now in the starting blocks for intense analysis of the data in the HARMONY Big Data platform. 

The HARMONY BigData Platform: What is it and how does it work? 

Despite data being a key driver for modern evidence-based medicine, we have been struggling with the same challenge for years: how can we have access to the scientific data that has been kept isolated and convert it into practical applications in order to make real progress in human sciences? The HARMONY BigData Platform is a significant step towards breaking down these silos and exploiting the potential of Big Data to improve the treatments and quality of care for patients with hematologic malignancies. Read more >

Insight into the HARMONY Anonymization, Data Quality, Safety, and Privacy

HARMONY’s Big Data research activities carry significant potential for improving cancer patients’ treatment options. Still, we take great care to follow ethical principles for biomedical research to ensure that no mistakes are made. One example is the question of personal data security. Moreover, we must ascertain the quality of the data and their analysis, as only sound science is ethically justifiable. Read more >


The HARMONY Alliance is a public-private European Network of Excellence, established in January 2017, to end in 2021. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more efficient treatment strategies. We currently have 53 Partners and 32 Associated Members from 22 countries, including 8 pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA). Read more >